Respiratory - Wiki-CORONA

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
EDN3 and EDNRA	endothelin 3	endothelin receptor type A	Peptide ligand-binding receptors G alpha (q) signalling events	Peptide ligand-binding receptors G alpha (q) signalling events		Bosentan Acetylsalicylic acid 2-HYDROXY-3,5-DIIODOBENZOIC ACID Darusentan SPP 301 Actelion-1 Sitaxentan Ambrisentan Macitentan Sparsentan	Hirschsprung disease (HD) Congenital central hypoventilation syndrome (CCHS) Waardenburg syndrome (WS)
EDNRA and HDAC7	endothelin receptor type A	histone deacetylase 7	Peptide ligand-binding receptors G alpha (q) signalling events	NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants SUMOylation of DNA damage response and repair proteins Notch-HLH transcription pathway Regulation of PTEN gene transcription	Bosentan Acetylsalicylic acid 2-HYDROXY-3,5-DIIODOBENZOIC ACID Darusentan SPP 301 Actelion-1 Sitaxentan Ambrisentan Macitentan Sparsentan	7-[4-(Dimethylamino)Phenyl]-N-Hydroxy-4,6-Dimethyl-7-Oxo-2,4-Heptadienamide Belinostat Panobinostat
EDNRA and GNAI2	endothelin receptor type A	G protein subunit alpha i2	Peptide ligand-binding receptors G alpha (q) signalling events	PLC beta mediated events PLC beta mediated events Adenylate cyclase inhibitory pathway Adenylate cyclase inhibitory pathway G-protein activation ADP signalling through P2Y purinoceptor 12 Adrenaline,noradrenaline inhibits insulin secretion Adrenaline,noradrenaline inhibits insulin secretion G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events G alpha (z) signalling events Regulation of insulin secretion Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding Extra-nuclear estrogen signaling ADORA2B mediated anti-inflammatory cytokines production	Bosentan Acetylsalicylic acid 2-HYDROXY-3,5-DIIODOBENZOIC ACID Darusentan SPP 301 Actelion-1 Sitaxentan Ambrisentan Macitentan Sparsentan			Adrenal carcinoma
EDNRA and GRK6	endothelin receptor type A	G protein-coupled receptor kinase 6	Peptide ligand-binding receptors G alpha (q) signalling events	G alpha (s) signalling events	Bosentan Acetylsalicylic acid 2-HYDROXY-3,5-DIIODOBENZOIC ACID Darusentan SPP 301 Actelion-1 Sitaxentan Ambrisentan Macitentan Sparsentan
EDNRA and GNA11	endothelin receptor type A	G protein subunit alpha 11	Peptide ligand-binding receptors G alpha (q) signalling events	Acetylcholine regulates insulin secretion Acetylcholine regulates insulin secretion G alpha (q) signalling events G alpha (q) signalling events ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1 Thromboxane signalling through TP receptor Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Thrombin signalling through proteinase activated receptors (PARs)	Bosentan Acetylsalicylic acid 2-HYDROXY-3,5-DIIODOBENZOIC ACID Darusentan SPP 301 Actelion-1 Sitaxentan Ambrisentan Macitentan Sparsentan
EDNRA and KAT5	endothelin receptor type A	lysine acetyltransferase 5	Peptide ligand-binding receptors G alpha (q) signalling events	Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex DNA Damage/Telomere Stress Induced Senescence HATs acetylate histones HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) Sensing of DNA Double Strand Breaks Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange Regulation of TP53 Activity through Phosphorylation G2/M DNA damage checkpoint Estrogen-dependent gene expression	Bosentan Acetylsalicylic acid 2-HYDROXY-3,5-DIIODOBENZOIC ACID Darusentan SPP 301 Actelion-1 Sitaxentan Ambrisentan Macitentan Sparsentan	Coenzyme A S-Acetyl-Cysteine
PHC2 and TMEM70	polyhomeotic homolog 2	transmembrane protein 70	Oxidative Stress Induced Senescence SUMOylation of DNA damage response and repair proteins SUMOylation of transcription cofactors SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA methylation proteins RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known Regulation of PTEN gene transcription Regulation of PTEN gene transcription
EEF1A1 and SDHAF2	eukaryotic translation elongation factor 1 alpha 1	succinate dehydrogenase complex assembly factor 2	Eukaryotic Translation Elongation Eukaryotic Translation Elongation Peptide chain elongation HSF1 activation Neutrophil degranulation Protein methylation Chaperone Mediated Autophagy		Zinc Guanosine-5'-Diphosphate Copper Artenimol
EEF1A1 and COX17	eukaryotic translation elongation factor 1 alpha 1	cytochrome c oxidase copper chaperone COX17	Eukaryotic Translation Elongation Eukaryotic Translation Elongation Peptide chain elongation HSF1 activation Neutrophil degranulation Protein methylation Chaperone Mediated Autophagy	Mitochondrial protein import	Zinc Guanosine-5'-Diphosphate Copper Artenimol
EFNB3 and YWHAZ	ephrin B3	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	EPH-Ephrin signaling EPH-Ephrin signaling EPHB-mediated forward signaling EPHB-mediated forward signaling Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells	Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Deactivation of the beta-catenin transactivating complex Rap1 signalling GP1b-IX-V activation signalling KSRP (KHSRP) binds and destabilizes mRNA Interleukin-3, Interleukin-5 and GM-CSF signaling RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex NOTCH4 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling Regulation of localization of FOXO transcription factors		Phenethyl Isothiocyanate
EGF and LMNA	epidermal growth factor	lamin A/C	Platelet degranulation Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Downregulation of ERBB2 signaling Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	XBP1(S) activates chaperone genes Signaling by BRAF and RAF fusions	Sucralfate Alpha-Aminobutyric Acid Tesevatinib		Gastric cancer	Restrictive dermopathy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Mandibuloacral dysplasia Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy Limb-girdle muscular dystrophy (LGMD) Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Hutchinson-Gilford progeria syndrome
EGFR and NDN	epidermal growth factor receptor	necdin, MAGE family member	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Interleukin-4 and Interleukin-13 signaling	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib Osimertinib Necitumumab Depatuxizumab mafodotin Icotinib Neratinib Zalutumumab Brigatinib Olmutinib		Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer	Prader-Willi and Angelman syndromes, including: Angelman syndrome (AS); Prader-Willi syndrome (PWS)
EGFR and HCK	epidermal growth factor receptor	HCK proto-oncogene, Src family tyrosine kinase	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Nef and signal transduction FCGR activation Regulation of signaling by CBL Regulation of signaling by CBL FLT3 Signaling FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib Osimertinib Necitumumab Depatuxizumab mafodotin Icotinib Neratinib Zalutumumab Brigatinib Olmutinib	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine Phosphonotyrosine Quercetin Bosutinib	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
EGFR and PLEC	epidermal growth factor receptor	plectin	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Assembly of collagen fibrils and other multimeric structures Caspase-mediated cleavage of cytoskeletal proteins Type I hemidesmosome assembly	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib Osimertinib Necitumumab Depatuxizumab mafodotin Icotinib Neratinib Zalutumumab Brigatinib Olmutinib		Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer	Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy Epidermolysis bullosa, hemidesmosomal, including: Epidermolysis bullosa, generalized atrophic benign (GABEB); Epidermolysis bullosa simplex with pyloric atresia (EBS-PA); Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD); Epidermolysis bullosa simplex, Ogna type (EBS-Ogna)
EGFR and YWHAZ	epidermal growth factor receptor	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Deactivation of the beta-catenin transactivating complex Rap1 signalling GP1b-IX-V activation signalling KSRP (KHSRP) binds and destabilizes mRNA Interleukin-3, Interleukin-5 and GM-CSF signaling RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex NOTCH4 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling Regulation of localization of FOXO transcription factors	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib Osimertinib Necitumumab Depatuxizumab mafodotin Icotinib Neratinib Zalutumumab Brigatinib Olmutinib	Phenethyl Isothiocyanate	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
EGFR and RAB3A	epidermal growth factor receptor	RAB3A, member RAS oncogene family	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Glutamate Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle Neutrophil degranulation RAB geranylgeranylation RAB GEFs exchange GTP for GDP on RABs GABA synthesis, release, reuptake and degradation	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib Osimertinib Necitumumab Depatuxizumab mafodotin Icotinib Neratinib Zalutumumab Brigatinib Olmutinib		Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
ELANE and GRN	elastase, neutrophil expressed	granulin precursor	Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases Neutrophil degranulation Antimicrobial peptides Regulation of Complement cascade	Neutrophil degranulation	Pegfilgrastim Alpha-1-proteinase inhibitor Filgrastim Mdl 101,146 Freselestat Elafin		Neutropenic disorders, including the following three diseases: Kostmann syndrome; Cyclic neutropenia; X-linked neutropenia/myelodysplasia	Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
ELANE and ELN	elastase, neutrophil expressed	elastin	Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases Neutrophil degranulation Antimicrobial peptides Regulation of Complement cascade	Degradation of the extracellular matrix Elastic fibre formation Molecules associated with elastic fibres Molecules associated with elastic fibres	Pegfilgrastim Alpha-1-proteinase inhibitor Filgrastim Mdl 101,146 Freselestat Elafin	Rofecoxib	Neutropenic disorders, including the following three diseases: Kostmann syndrome; Cyclic neutropenia; X-linked neutropenia/myelodysplasia	Congenital supravalvar aortic stenosis Cutis laxa, including: Autosomal dominant cutis laxa (ADCL); Autosomal recessive cutis laxa I (ARCL1); Autosomal recessive cutis laxa II (ARCL2); X-linked recessive cutis laxa (XRCL); Wrinkly skin syndrome
ELAVL3 and ECSIT	ELAV like RNA binding protein 3	ECSIT signaling integrator		MyD88:MAL(TIRAP) cascade initiated on plasma membrane Complex I biogenesis TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 cascade initiated on plasma membrane
ELN and LOXL1	elastin	lysyl oxidase like 1	Degradation of the extracellular matrix Elastic fibre formation Molecules associated with elastic fibres Molecules associated with elastic fibres	Elastic fibre formation Crosslinking of collagen fibrils	Rofecoxib		Congenital supravalvar aortic stenosis Cutis laxa, including: Autosomal dominant cutis laxa (ADCL); Autosomal recessive cutis laxa I (ARCL1); Autosomal recessive cutis laxa II (ARCL2); X-linked recessive cutis laxa (XRCL); Wrinkly skin syndrome

Search Results for: Respiratory